Impact of high-dose chemotherapy and autologous transplantation as first-line therapy on the survival of high-risk diffuse large B cell lymphoma patients: a single-center study in Japan

International Journal of Hematology
Shojiro InanoNobuyoshi Arima

Abstract

High-dose chemotherapy (HDT), together with autologous stem cell transplantation (ASCT), plays an important role in the treatment of diffuse large B cell lymphoma (DLBCL), especially as second-line therapy. However, its significance in up-front settings remains to be elucidated. In our institute, patients with DLBCL in both the high-intermediate and high international prognostic index (IPI) groups initially underwent CHOP/R-CHOP treatment followed by HDT/ASCT at upfront settings between 2002 and 2011. We retrospectively analyzed 25 patients who were all treated with upfront HDT/ASCT. We excluded one patient who failed to undergo transplantation because of primary refractory disease from the analysis. The median follow-up was 77 months (range 17-110 months). Five-year overall survival (OS) and progression-free survival (PFS) were 91.7 and 79.2 %, respectively, which were higher than the equivalents in previous studies. The OS and PFS in the high-risk group were lower than those in the high-intermediate group. Treatment-related mortalities or fatal complication were not observed. Our results confirm that HDT/ASCT for high-risk aggressive lymphoma is a feasible and promising therapy, but patients with high IPI continued to have po...Continue Reading

References

Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W MillsA H Goldstone
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M A ShippB Coiffier
Mar 27, 2004·The New England Journal of Medicine·Noel MilpiedUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marita ZiepertMarkus Loeffler
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corrado TarellaAlessandro Rambaldi
Oct 19, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolas MounierUNKNOWN Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT)
Oct 23, 2012·International Journal of Hematology·Mark RoschewskiWyndham H Wilson
Dec 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N KettererC Haioun

❮ Previous
Next ❯

Citations

Aug 28, 2020·Leukemia & Lymphoma·Yoshiaki ChinenUNKNOWN Kyoto Clinical Hematology Study Group investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.